Charles Sawyers

Author PubWeight™ 26.24^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.	N Engl J Med	2002	8.86
2	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nat Genet	2012	5.64
3	Gene expression changes associated with progression and response in chronic myeloid leukemia.	Proc Natl Acad Sci U S A	2006	3.70
4	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.	Blood	2007	1.93
5	Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation.	Oncogene	2002	1.71
6	Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.	Cancer Res	2006	1.55
7	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.	Blood	2005	1.23
8	Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.	Prostate	2010	0.86
9	Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.	Cancer Genet	2011	0.83
10	The imperative to invest in science has never been greater.	J Clin Invest	2014	0.82